Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 617

1.

Action of RANKL and OPG for osteoclastogenesis.

Kobayashi Y, Udagawa N, Takahashi N.

Crit Rev Eukaryot Gene Expr. 2009;19(1):61-72. Review.

PMID:
19191757
2.

Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.

Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM, Lee ZH.

Eur J Pharmacol. 2009 Nov 25;623(1-3):22-9. doi: 10.1016/j.ejphar.2009.09.025. Epub 2009 Sep 17.

PMID:
19766111
3.

Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.

Lee JW, Iwahashi A, Hasegawa S, Yonezawa T, Jeon WB, Cha BY, Nagai K, Woo JT.

J Nat Med. 2012 Jan;66(1):8-16. doi: 10.1007/s11418-011-0537-7. Epub 2011 Jun 9.

PMID:
21656335
4.
5.

Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.

Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6.

PMID:
23928189
6.

Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.

Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y.

Bone. 2007 Aug;41(2):165-74. Epub 2007 May 5.

PMID:
17560185
7.

Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals.

Takahashi N, Maeda K, Ishihara A, Uehara S, Kobayashi Y.

Front Biosci (Landmark Ed). 2011 Jan 1;16:21-30. Review.

PMID:
21196156
8.

Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.

Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY.

J Bone Miner Res. 2006 Oct;21(10):1648-56.

9.

DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.

Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F.

Bone. 2007 Apr;40(4):981-90. Epub 2006 Dec 28.

PMID:
17196895
10.

Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.

Tsuji-Naito K.

Bioorg Med Chem. 2008 Oct 15;16(20):9176-83. doi: 10.1016/j.bmc.2008.09.036. Epub 2008 Sep 14.

PMID:
18823786
11.

Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.

Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.

Bone. 2007 Oct;41(4):592-602. Epub 2007 Jun 13.

PMID:
17627913
12.

RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.

Iwai K, Koike M, Ohshima S, Miyatake K, Uchiyama Y, Saeki Y, Ishii M.

J Bone Miner Res. 2007 Oct;22(10):1612-20.

13.

NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.

Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF.

J Biol Chem. 2007 Jun 22;282(25):18245-53. Epub 2007 May 7.

15.

[Genomic approaches to bone and joint diseases. Mutations of RANK, OPG and RANKL genes found in humans].

Kobayashi Y, Takahashi N.

Clin Calcium. 2008 Feb;18(2):202-9. doi: CliCa0802202209. Review. Japanese.

PMID:
18245890
17.

Osteoprotegerin and inflammation.

Saidenberg Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC.

Eur Cytokine Netw. 2002 Apr-Jun;13(2):144-53. Review.

PMID:
12101070
18.

Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation.

Negishi-Koga T, Takayanagi H.

Immunol Rev. 2009 Sep;231(1):241-56. doi: 10.1111/j.1600-065X.2009.00821.x. Review.

PMID:
19754901
19.

The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.

Peng S, Liu XS, Huang S, Li Z, Pan H, Zhen W, Luk KD, Guo XE, Lu WW.

Bone. 2011 Dec;49(6):1290-8. doi: 10.1016/j.bone.2011.08.031. Epub 2011 Sep 9.

PMID:
21925296
20.

Mechanistic insight into osteoclast differentiation in osteoimmunology.

Takayanagi H.

J Mol Med (Berl). 2005 Mar;83(3):170-9. Epub 2005 Jan 26. Review.

PMID:
15776286
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk